

Angelo Ravelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2230688/angelo-ravelli-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

329
papers

18,635
citations

71
h-index

125
g-index

358
ext. papers

21,808
ext. citations

5
avg, IF

6.38
L-index

#	Paper	IF	Citations
329	Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): Distinct from Kawasaki disease or part of the same spectrum?. <i>Pediatric Allergy and Immunology</i> , 2022 , 33 Suppl 27, 102-104	4.2	1
328	Cardiovascular Manifestations in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 According to Age. <i>Children</i> , 2022 , 9, 583	2.8	0
327	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study. <i>Rheumatology</i> , 2021 , 60, 3388-3397	3.9	5
326	Comparison Between Clinical and Ultrasound Assessment of the Ankle Region in Children With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1180-1186	4.7	2
325	Multifactorial Posterior Reversible Encephalopathy Syndrome in Children: Clinical, Laboratory, and Neuroimaging Findings. <i>Journal of Pediatric Neurology</i> , 2021 , 19, 083-091	0.2	1
324	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. <i>Rheumatology</i> , 2021 , 60, 3176-3188	3.9	4
323	Determinants of Discordance Between Criteria for Inactive Disease and Low Disease Activity in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1722-1729	4.7	0
322	Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report. <i>Journal of Pediatric Hematology/Oncology</i> , 2021 , 43, e1168-e1172	1.2	2
321	Neutrophil Extracellular Traps in the Autoimmunity Context. <i>Frontiers in Medicine</i> , 2021 , 8, 614829	4.9	5
320	Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey. <i>Pediatric Rheumatology</i> , 2021 , 19, 29	3.5	22
319	The challenge of early diagnosis of autoimmune lymphoproliferative syndrome in children with suspected autoinflammatory/autoimmune disorders. <i>Rheumatology</i> , 2021 ,	3.9	3
318	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 1217-1225	11.5	30
317	Expanding the clinical and neuroimaging features of post-varicella arteriopathy of childhood. <i>Journal of Neurology</i> , 2021 , 268, 4846-4865	5.5	0
316	Multisystem Inflammatory Syndrome in Children: Unique Disease or Part of the Kawasaki Disease Spectrum?. <i>Frontiers in Pediatrics</i> , 2021 , 9, 680813	3.4	10
315	Response to MS score in systemic juvenile idiopathic arthritis: suitable for routine use? By Chi. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e108	2.4	2
314	Response to Application of MS score in macrophage activation syndrome patients associated with adult onset Still disease By Wang. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e146	2.4	1
313	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. <i>Journal of Rheumatology</i> , 2021 , 48, 898-906	4.1	2

312	Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease. <i>Italian Journal of Pediatrics</i> , 2021 , 47, 16	3.2	17
311	Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. <i>Current Rheumatology Reports</i> , 2021 , 23, 10	4.9	1
310	Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers. <i>Rheumatology</i> , 2021 , 60, 5419-5423	3.9	2
309	Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. <i>Italian Journal of Pediatrics</i> , 2021 , 47, 24	3.2	28
308	The controversial role of wellbeing assessment in juvenile idiopathic arthritis. <i>Lancet Rheumatology, The</i> , 2021 , 3, e85-e86	14.2	0
307	Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e507-e516	14.2	3
306	Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 853-870	5.1	3
305	Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients. <i>Journal of Pediatrics</i> , 2021 , 235, 196-202	3.6	1
304	CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REAL-LIFE DATA FROM A RETROSPECTIVE ITALIAN COHORT. <i>Rheumatology</i> , 2021 ,	3.9	1
303	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score[Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1966-1975	9.5	4
302	Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD). <i>Clinical Immunology</i> , 2021 , 231, 108837	9	1
301	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	0
300	Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 426-433	2.2	
299	Neonatal lupus erythematosus in dizygotic twins with anti-RNP antibodies. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 1446	2.2	1
298	A prediction rule for polyarticular extension in oligoarticular-onset juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 913-919	2.2	
297	Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients With MIS-C: Proposal for a Severity Score.. <i>Frontiers in Pediatrics</i> , 2021 , 9, 783745	3.4	2
296	Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 213-215	11.5	90
295	Evaluating diagnostic criteria for macrophage activation syndrome in patients with adult onset Still's disease. Response to: Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease associated macrophage activation syndrome by Zhang. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2

294	Macrophage activation syndrome in pediatrics. <i>Pediatric Allergy and Immunology</i> , 2020 , 31 Suppl 24, 13-14	5
293	Medicine and humanism in the time of COVID-19. Ethical choices. <i>Acta Biomedica</i> , 2020 , 91, e2020167	3-2
292	The Effect of Morning Stiffness Duration on the Definition of Clinically Inactive Disease in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2020 , 47, 1238-1241	4-1 1
291	Update on Outcome Measures for Pediatric Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 163-170	4-7 0
290	Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases. <i>Pediatric Rheumatology</i> , 2020 , 18, 56	3-5 1
289	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , 2020 , 59, 3505-3514	3-9 16
288	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. <i>Arthritis Research and Therapy</i> , 2020 , 22, 211	5-7 2
287	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. <i>Journal of Rheumatology</i> , 2020 , 47, 377-386	4-1 36
286	Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. <i>Arthritis Care and Research</i> , 2020 , 72, 265-273	4-7 3
285	Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers. <i>Rheumatology</i> , 2020 , 59, 344-360	3-9 19
284	On the Alert for Cytokine Storm: Immunopathology in COVID-19. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1059-1063	9-5 394
283	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. <i>Rheumatology</i> , 2019 , 58, 1196-1205	3-9 7
282	The European network for care of children with paediatric rheumatic diseases: care across borders. <i>Rheumatology</i> , 2019 , 58, 1188-1195	3-9 11
281	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019 , 71, 579-590	4-7 12
280	Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019 , 46, 416-421	4-1 20
279	Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. <i>Journal of Clinical Immunology</i> , 2019 , 39, 476-485	5-7 43
278	The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. <i>Pediatric Rheumatology</i> , 2019 , 17, 24	3-5 8
277	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019 , 3, 255-263	14-5 58

276	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1357-1362 ^{2,4}	44
275	Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. <i>Arthritis Research and Therapy</i> , 2019 , 21, 168	5.7 16
274	A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019 , 17, 50	3.5 2
273	Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>ACR Open Rheumatology</i> , 2019 , 1, 345-349 ^{3,5}	37
272	Criteria for Cytokine Storm Syndromes 2019 , 61-79	
271	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019 , 46, 1006-1013	4.1 18
270	Dr. Tibaldi, reply. <i>Journal of Rheumatology</i> , 2019 , 46, 1424	4.1 1
269	Acute pain management in children: a survey of Italian pediatricians. <i>Italian Journal of Pediatrics</i> , 2019 , 45, 156	3.2 2
268	Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. <i>Arthritis Research and Therapy</i> , 2019 , 21, 275	5.7 10
267	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides - the SHARE initiative. <i>Rheumatology</i> , 2019 , 58, 656-671	3.9 50
266	Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1011-1021	9.5 31
265	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. <i>Journal of Rheumatology</i> , 2019 , 46, 190-197	4.1 139
264	Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 1084-1091	2.2 2
263	American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 813-822	4.7 16
262	Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis. <i>Current Rheumatology Reports</i> , 2018 , 20, 29	4.9 4
261	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 819-828	2.4 99
260	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018 , 38, 251-258	3.6 1
259	Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 1621-1629	4.7 16

258	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. <i>Arthritis Care and Research</i> , 2018 , 70, 1312-1319	4.7	14
257	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. <i>Rheumatology International</i> , 2018 , 38, 5-17	3.6	64
256	Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1107-1117	2.4	70
255	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2018 , 70, 409-419	4.7	72
254	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 319-327	2.4	6
253	Type I interferon pathway activation in COPA syndrome. <i>Clinical Immunology</i> , 2018 , 187, 33-36	9	68
252	In silico validation of the Autoinflammatory Disease Damage Index. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1599-1605	2.4	17
251	Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. <i>Pediatric Rheumatology</i> , 2018 , 16, 46	3.5	50
250	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 241-250	2.4	20
249	Disease activity, overweight, physical activity and screen time in a cohort of patients with juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 1110-1116	2.2	4
248	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. <i>Lancet, The</i> , 2017 , 389, 909-916	4.0	34
247	Development of the autoinflammatory disease damage index (ADDI). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 821-830	2.4	54
246	Elevated circulating levels of interferon- γ and interferon- γ -induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 166-172	2.4	154
245	Consensus-based recommendations for the management of juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 329-340	2.4	119
244	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1637-1641	2.4	59
243	ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1648-1656	2.4	139
242	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1788-1796	2.4	90
241	Update on the pathogenesis and treatment of juvenile idiopathic arthritis. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 523-529	5.3	29

240	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017 , 69, 911-922	9.5	36
239	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017 , 69, 898-910	9.5	33
238	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 782-791	2.4	24
237	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1965-1973	2.4	65
236	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. <i>Journal of Pediatrics</i> , 2017 , 189, 72-78.e3	3.6	37
235	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1884-1888	4.1	8
234	Paediatric rheumatic disease: What is the best definition of clinical remission in JIA?. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 460-461	8.1	3
233	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2017 , 69, 677-686	4.7	32
232	Recent therapeutic advances in juvenile idiopathic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 476-487	5.3	6
231	Macrophage Activation Syndrome 2017 , 275-292		
230	Open issues in the assessment and management of pain in juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 107, 123-126	2.2	7
229	Juvenile Idiopathic Arthritis: Diagnosis and Treatment. <i>Rheumatology and Therapy</i> , 2016 , 3, 187-207	4.4	102
228	Clinical outcome measures in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2016 , 14, 23	3.5	74
227	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016 , 2, e000161	5.9	46
226	Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases. <i>Current Rheumatology Reports</i> , 2016 , 18, 8	4.9	9
225	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 481-9	2.4	247
224	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. <i>Lancet, The</i> , 2016 , 387, 671-678	4.0	124
223	Clinical manifestations 2016 , 25-34		0

222	Consequences and complications 2016 , 59-71		0
221	General treatment aspects 2016 , 73-85		0
220	Management of Patients with Juvenile Idiopathic Arthritis 2016 , 87-114		0
219	Specific Issues 2016 , 115-120		
218	Disease classification 2016 , 17-24		
217	Outcome, Prognosis and Future Outlook 2016 , 121-124		
216	PROMs for Juvenile Idiopathic Arthritis 2016 , 209-224		
215	IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2016 , 7, 467	5.6	33
214	The PRINTO juvenile dermatomyositis trial - AuthorsReply. <i>Lancet, The</i> , 2016 , 387, 2601	4.0	
213	Delineating the Application of Ultrasound in Detecting Synovial Abnormalities of the Subtalar Joint in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1346-53	4.7	13
212	A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1540-50	9.5	10
211	Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. <i>RMD Open</i> , 2016 , 2, e000302	5.9	35
210	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. <i>Pediatric Rheumatology</i> , 2016 , 14, 68	3.5	28
209	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis Care and Research</i> , 2016 , 68, 511-514	9.5	216
208	Recurrent macrophage activation syndrome in spondyloarthritis and monoallelic missense mutations in PRF1: a description of one paediatric case. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 719	2.2	5
207	Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 714-8	2.2	10
206	Information technology in paediatric rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, S11-S16	2.2	4
205	Clinical features and correct diagnosis of macrophage activation syndrome. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 1043-53	5.1	45

204	Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 994-1001	4.1	47
203	Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference. <i>Autoimmunity Reviews</i> , 2015 , 14, 692-702	13.6	49
202	Macrophage Activation Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 927-41	3.1	87
201	Advances in biomarkers for paediatric rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 265-75	8.1	23
200	Glucocorticoids in juvenile idiopathic arthritis. <i>NeuroImmunoModulation</i> , 2015 , 22, 112-8	2.5	12
199	Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2015 , 13, 55	3.5	43
198	Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. <i>Trials</i> , 2015 , 16, 268	2.8	15
197	Evaluation of musculoskeletal complaints in children: Clinical evaluation 2015 , 815-819		
196	The conundrum of juvenile psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S40-3	2.2	27
195	Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. <i>Arthritis and Rheumatology</i> , 2014 , 66, 3160-9	9.5	248
194	A30: Assessment of Construct and Discriminative Validity of the 3-Variable JADAS in Relation of Parent-Reported Outcomes. <i>Arthritis and Rheumatology</i> , 2014 , 66, S46-S46	9.5	1
193	Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1380-3	2.4	56
192	Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2871-80	9.5	84
191	Developing a provisional, international minimal dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research. <i>Pediatric Rheumatology</i> , 2014 , 12, 31	3.5	6
190	Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 1416-25	4.1	21
189	Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?. <i>Pediatric Rheumatology</i> , 2014 , 12,	3.5	78
188	Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. <i>Arthritis Care and Research</i> , 2014 , 66, 1703-9	4.7	78
187	CACP syndrome: identification of five novel mutations and of the first case of UPD in the largest European cohort. <i>European Journal of Human Genetics</i> , 2014 , 22, 197-201	5.3	19

186	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. <i>Arthritis and Rheumatology</i> , 2014 , 66, S96-S97	9.5	1
185	A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab. <i>Arthritis and Rheumatology</i> , 2014 , 66, S83-S84	9.5	11
184	Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 27-33	4.7	7
183	Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 34-9	4.7	3
182	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014 , 66, S17-S18	9.5	4
181	Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration. <i>Pediatric Rheumatology</i> , 2014 , 12, 49	3.5	5
180	Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2014 , 12,	3.5	6
179	Is it worth allowing the presence of morning stiffness in the definition of inactive disease in juvenile idiopathic arthritis?. <i>Pediatric Rheumatology</i> , 2014 , 12, P174	3.5	78
178	Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. <i>Pediatric Rheumatology</i> , 2014 , 12,	3.5	78
177	Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. <i>Pediatric Rheumatology</i> , 2014 , 12,	3.5	4
176	The functional significance of common polymorphisms in zinc finger transcription factors. <i>G3: Genes, Genomes, Genetics</i> , 2014 , 4, 1647-55	3.2	6
175	Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1083-90	2.4	94
174	Treating Juvenile Idiopathic Arthritis According to JADAS-Based Targets. <i>Annals of Paediatric Rheumatology</i> , 2014 , 3, 4		8
173	Evaluation of Biopsychosocial Aspects of Patients with Juvenile Autoinflammatory Disease: A Qualitative Study. <i>Annals of Paediatric Rheumatology</i> , 2014 , 3, 62		4
172	The invisible part of the iceberg: qualitative aspects of childhood vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, S122-7	2.2	4
171	Periostin gene variants are associated with disease course and severity in juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, 747-53	2.2	3
170	MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 363-8	2.4	28
169	Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. <i>Arthritis Care and Research</i> , 2013 , 65, 1112-20	4.7	32

168	Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. <i>Journal of Pediatrics</i> , 2013 , 163, 879-84	3.6	38
167	Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. <i>Journal of Rheumatology</i> , 2013 , 40, 192-200	4.1	39
166	Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 223-8	2.4	66
165	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 686-93	2.4	84
164	Towards a role of ultrasound in children with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2013 , 52, 413-20.9		33
163	Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1503-9	2.4	11
162	Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 964-8	2.2	8
161	A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. <i>Arthritis and Rheumatism</i> , 2012 , 64, 557-67		147
160	Macrophage activation syndrome. <i>Indian Journal of Rheumatology</i> , 2012 , 7, 27-35	0.5	4
159	Novel automated system for magnetic resonance imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 1657-64	4.7	14
158	Advances and challenges in imaging in juvenile idiopathic arthritis. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 329-36	8.1	61
157	Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. <i>Pediatric Rheumatology</i> , 2012 , 10, 39	3.5	63
156	Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. <i>New England Journal of Medicine</i> , 2012 , 367, 2385-95	59.2	577
155	Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. <i>Genes and Immunity</i> , 2012 , 13, 289-98	4.4	261
154	Inactive disease and remission in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012 , 64, 683-93	4.7	29
153	Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2366-74		123
152	A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 511-7	2.4	44
151	Parent and child acceptable symptom state in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2012 , 39, 856-63	4.1	64

150	Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>Annals of Paediatric Rheumatology</i> , 2012 , 1, 1		13
149	Recent advances in quantitative assessment of juvenile idiopathic arthritis. <i>Annals of Paediatric Rheumatology</i> , 2012 , 1, 84		5
148	Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S162-8	2.2	13
147	Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S157-62	2.2	33
146	Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. <i>Autoimmunity Reviews</i> , 2011 , 11, 112-22	13.6	44
145	Criteria to define response to therapy in paediatric rheumatic diseases. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67 Suppl 1, 125-31	2.8	21
144	Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2011 , 9,	3.5	78
143	Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2011 , 9,	3.5	78
142	Proposal for the development of an international minimal data collection for juvenile dermatomyositis (JDM). <i>Pediatric Rheumatology</i> , 2011 , 9, P51	3.5	78
141	Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011 , 63, 1213-23	4.7	25
140	Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011 , 63, 1262-70	4.7	15
139	Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Childhood Consensus Assessment of Disease Activity (CHAIDA), and Systemic Lupus	4.7	42
138	Antinuclear antibody-positive patients should be grouped as a separate category in the ILIC/ACR classification of juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 267-75		109
137	Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3142-52		42
136	Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 440-6	2.4	46
135	An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 764-8	4.1	120
134	Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2011 , 50, 1627-34	3.9	48
133	A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. <i>Journal of Rheumatology</i> , 2011 , 38, 938-53	4.1	122

132	EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1704-12	2.4	142
131	Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, 117-24	2.2	31
130	Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 1266-73	27.4	184
129	Does removal of aids/devices and help make a difference in the Childhood Health Assessment Questionnaire disability index?. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 82-7	2.4	10
128	Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1479-83	2.4	37
127	Development and initial validation of a radiographic scoring system for the hip in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 432-9	4.1	30
126	Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. <i>Rheumatology</i> , 2010 , 49, 441-9	3.9	169
125	A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2010 , 49, 1272-80	3.9	36
124	Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2010 , 49, 178-85	3.9	58
123	EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 790-7	2.4	140
122	Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 1534-41	4.1	98
121	Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. <i>Arthritis Care and Research</i> , 2010 , 62, 63-72	4.7	164
120	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. <i>Arthritis Care and Research</i> , 2010 , 62, 1533-41	4.7	63
119	Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, 424-33	3.2	3
118	Factors affecting survival in juvenile systemic sclerosis. <i>Rheumatology</i> , 2009 , 48, 119-22	3.9	61
117	Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2009 , 36, 628-34	4.1	47
116	Developing outcome measures for paediatric rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 609-24	5.3	35
115	Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. <i>Arthritis and Rheumatism</i> , 2009 , 61, 509-17		36

114	Development and validation of a composite disease activity score for juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 658-66		424
113	Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1497-504		123
112	Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3388-99		192
111	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3425-35		83
110	HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. <i>Pediatric Pulmonology</i> , 2009 , 44, 1226-34	3.5	21
109	The Ped-APS Registry: the antiphospholipid syndrome in childhood. <i>Lupus</i> , 2009 , 18, 894-9	2.6	43
108	Development and testing of reduced joint counts in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2009 , 36, 183-90	4.1	31
107	Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. <i>Journal of Pediatrics</i> , 2008 , 153, 432-4	3.6	42
106	Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. <i>Pediatrics</i> , 2008 , 122, e1100-7	7.4	151
105	A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1159-64	2.4	28
104	Consensus procedures and their role in pediatric rheumatology. <i>Current Rheumatology Reports</i> , 2008 , 10, 142-6	4.9	40
103	The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. <i>Arthritis and Rheumatism</i> , 2008 , 50, 4-13		114
102	The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1505-15		290
101	Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1112-9		31
100	Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1120-7		80
99	Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1571-9		47
98	Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1764-72		102
97	The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 370-4	2.4	51

96	Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 309-14	2.4	44
95	Juvenile idiopathic arthritis 2008 , 789-801		
94	Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication?. <i>Lupus</i> , 2007 , 16, 587-92	2.6	52
93	Antiphospholipid syndrome in pediatrics. <i>Rheumatic Disease Clinics of North America</i> , 2007 , 33, 499-523	2.4	23
92	Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. <i>Arthritis and Rheumatism</i> , 2007 , 57, 35-43		106
91	The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007 , 57, 203-12		127
90	Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3087-95		71
89	A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3096-106		315
88	Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 57, 913-20		88
87	Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2007 , 5, 23	3.5	14
86	Chapter 4 Macrophage Activation Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007 , 55-275	0.3	1
85	The Paediatric Rheumatology International Trials Organization (PRINTO). <i>Lupus</i> , 2007 , 16, 670-6	2.6	12
84	Macrophage Activation Syndrome in Childhood Rheumatic Diseases. <i>Current Rheumatology Reviews</i> , 2007 , 3, 225-230	1.6	1
83	Discordance between physician and parent global assessments in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2007 , 46, 141-5	3.9	30
82	Juvenile idiopathic arthritis. <i>Lancet, The</i> , 2007 , 369, 767-778	4.0	991
81	Physicians and parents ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 1773-6	4.1	28
80	Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 55, 177-83		60
79	The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement. <i>Arthritis and Rheumatism</i> , 2006 , 55, 255-63		66

78	A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2989-96		111
77	Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3971-8		156
76	Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2006 , 55, 717-23		56
75	Reply to letter by Isenberg and Gordon commenting on the Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3723-4		1
74	Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease. <i>Arthritis and Rheumatism</i> , 2006 , 55, 843-9		37
73	Clinical assessment in juvenile dermatomyositis. <i>Autoimmunity</i> , 2006 , 39, 197-203	3	17
72	Weighting improves the information provided by joint counts on the severity of arthritis and its impact on patients' well-being in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2006 , 45, 343-7	3.9	8
71	Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 515-20	2.6	68
70	EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 936-41	2.4	531
69	Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2006 , 33, 789-95	4.1	43
68	Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Journal of Pediatrics</i> , 2005 , 146, 598-604	3.6	304
67	Antiphospholipid syndrome. <i>Pediatric Clinics of North America</i> , 2005 , 52, 469-91, vi	3.6	38
66	Outcome in juvenile onset systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 568-73	5.3	63
65	Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. <i>Arthritis and Rheumatism</i> , 2005 , 52, 826-32		171
64	Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2092-102		115
63	The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2854-64		70
62	Patterns of clinical remission in select categories of juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3554-62		169
61	Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 257-61	2.4	26

60	The Long-Term Outcome of Juvenile Idiopathic Arthritis. <i>Current Rheumatology Reviews</i> , 2005 , 1, 151-155.6		1
59	Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2005 , 32, 1805-10	4.1	24
58	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. <i>Rheumatology</i> , 2004 , 43, 49-54	3.9	249
57	Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. <i>Arthritis and Rheumatism</i> , 2004 , 51, 458-64		78
56	Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis. <i>Journal of Rheumatology</i> , 2004 , 31, 795-800	4.1	28
55	Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1398-407		156
54	Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. <i>Arthritis and Rheumatism</i> , 2003 , 49, 488-93		24
53	Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. <i>Arthritis and Rheumatism</i> , 2003 , 49, 501-7		126
52	Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3509-17		88
51	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. <i>British Journal of Rheumatology</i> , 2003 , 42, 1452-9		183
50	Outcome of primary antiphospholipid syndrome in childhood. <i>Lupus</i> , 2003 , 12, 449-53	2.6	53
49	Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. <i>Journal of Clinical Oncology</i> , 2003 , 21, 172-3	2.2	10
48	Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 232-7		60
47	Self epitopes shared between human skeletal myosin and <i>Streptococcus pyogenes</i> M5 protein are targets of immune responses in active juvenile dermatomyositis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 3015-25		47
46	Macrophage activation syndrome. <i>Current Opinion in Rheumatology</i> , 2002 , 14, 548-52	5.3	209
45	Visceral leishmaniasis as a cause of unexplained fever and cytopenia in systemic lupus erythematosus. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2002 , 91, 246-7	3.1	2
44	Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1405-9		84
43	Juvenile idiopathic arthritis: will etanercept be an improvement over current therapies?. <i>BioDrugs</i> , 2000 , 14, 93-8	7.9	

42	Responsiveness of outcome measures in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. <i>British Journal of Rheumatology</i> , 1999 , 38, 176-80		27
41	Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. <i>Rheumatology</i> , 1999 , 38, 773	3.9	11
40	Wegener granulomatosis in a child: cutaneous findings as the presenting signs. <i>Pediatric Dermatology</i> , 1999 , 16, 277-80	1.9	17
39	Aortic valve regurgitation as the presenting sign of Takayasu arteritis. <i>European Journal of Pediatrics</i> , 1999 , 158, 281-3	4.1	12
38	Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 807-11		63
37	The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. <i>Journal of Pediatrics</i> , 1999 , 135, 316-20	3.6	49
36	Wegener's granulomatosis presenting with life-threatening pulmonary hemorrhage in a boy with type 1 diabetes. <i>Diabetes Care</i> , 1999 , 22, 1591-2	14.6	3
35	Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. <i>Journal of Pediatrics</i> , 1998 , 133, 262-5	3.6	55
34	Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. <i>Annals of the Rheumatic Diseases</i> , 1998 , 57, 38-41	2.4	67
33	Correlation between conventional disease activity measures in juvenile chronic arthritis. <i>Annals of the Rheumatic Diseases</i> , 1997 , 56, 197-200	2.4	64
32	Cytokines in juvenile rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 1997 , 9, 428-33	5.3	34
31	The clinical significance of antiphospholipid antibodies. <i>Annals of Medicine</i> , 1997 , 29, 159-63	1.5	26
30	Antiphospholipid antibody syndrome in pediatric patients. <i>Rheumatic Disease Clinics of North America</i> , 1997 , 23, 657-76	2.4	53
29	Preliminary definition of improvement in juvenile arthritis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1202-1209		28
28	Preliminary definition of improvement in juvenile arthritis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1202-9		829
27	Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. <i>Neuropediatrics</i> , 1996 , 27, 149-53	1.6	58
26	Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. <i>Journal of Pediatrics</i> , 1996 , 128, 275-8	3.6	124
25	IgA nephropathy and Henoch-Schonlein syndrome occurring in the same patient. <i>Nephron</i> , 1996 , 72, 111-13	3.2	17

24	Pulmonary function in children with systemic lupus erythematosus. <i>Thorax</i> , 1996 , 51, 424-8	7.3	11
23	Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis. <i>Clinical Rheumatology</i> , 1995 , 14, 322-6	3.9	22
22	Frequency and complications of chronic iridocyclitis in ANA-positive pauciarticular juvenile chronic arthritis. <i>International Ophthalmology</i> , 1994 , 18, 225-8	2.2	8
21	Anticardiolipin antibodies in pediatric systemic lupus erythematosus. <i>JAMA Pediatrics</i> , 1994 , 148, 398-402		64
20	Antiphospholipid antibodies in paediatrics. <i>European Journal of Pediatrics</i> , 1994 , 153, 472-9	4.1	25
19	Antiphospholipid antibodies in children with idiopathic cerebral ischaemia. <i>Lancet, The</i> , 1994 , 344, 1232-40	4.0	7
18	Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. <i>Lancet, The</i> , 1994 , 344, 1052-4	4.0	55
17	Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations. <i>Journal of Pediatrics</i> , 1994 , 124, 742-4	3.6	46
16	Antiphospholipid antibody syndrome as a cause of venous thrombosis in childhood. <i>Journal of Pediatrics</i> , 1994 , 124, 831-2	3.6	5
15	Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. <i>Journal of Pediatrics</i> , 1994 , 124, 561-5	3.6	49
14	Anti-DNA antibodies in the primary antiphospholipid syndrome. <i>Rheumatology</i> , 1993 , 32, 1028	3.9	3
13	Chronic intoxication by ethane-1-hydroxy-1,1-diphosphonate (EHDP) in a child with myositis ossificans progressiva. <i>Pediatric Radiology</i> , 1993 , 23, 459-62	2.8	5
12	Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis. <i>Archives of Disease in Childhood</i> , 1992 , 67, 1384-5	2.2	31
11	Recurrent juvenile dermatomyositis and cutaneous necrotizing arteritis with molecular mimicry between streptococcal type 5 M protein and human skeletal myosin. <i>Journal of Pediatrics</i> , 1992 , 121, 739-42	3.6	30
10	Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1991 , 34, 1158-63		285
9	Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. <i>Annals of the Rheumatic Diseases</i> , 1991 , 50, 599-601	2.4	42
8	Methotrexate hepatotoxic effects in children with juvenile rheumatoid arthritis. <i>Journal of Pediatrics</i> , 1991 , 119, 333-4	3.6	13
7	Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis. <i>Annals of the Rheumatic Diseases</i> , 1989 , 48, 582-5	2.4	2

6	Frequency of autoantibodies in normal children. <i>JAMA Pediatrics</i> , 1989 , 143, 493-6		11
5	Systemic vasculitis followed by chronic myelogenous leukemia. <i>Pediatric Hematology and Oncology</i> , 1988 , 5, 315-8	1.7	
4	Systemic lupus erythematosus with Jaccoud's arthropathy mimicking juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1987 , 30, 1062-4		24
3	Urinary microscopy in the diagnosis of haematuria in Schölein-Henoch purpura. <i>European Journal of Pediatrics</i> , 1986 , 144, 591-3	4.1	4
2	IgG subclass serum levels in juvenile chronic arthritis. <i>Annals of the Rheumatic Diseases</i> , 1986 , 45, 400-4	2.4	7
1	Henoch-Schölein syndrome and selective IgA deficiency. <i>Archives of Disease in Childhood</i> , 1985 , 60, 160-22.2		10